Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
BridgeBio Has More Room To Run
12:41pm, Tuesday, 23'rd Dec 2025
BridgeBio had a very successful 2025 with a strong commercial launch of Attruby and successful phase 3 readouts of BBP-418 and infigratinib. I expect 2026 to be another strong year with Attruby U.S. n
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Monday, 22'nd Dec 2025
PALO ALTO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages
01:32am, Monday, 22'nd Dec 2025
Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-two ratings firms that are presently covering the stock, Ma
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO
03:25am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. decreased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 26.1% in the undefined quarter, according to its most recent Form 13F filing with the SEC.
Neil Kumar Sells 30,011 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
04:42am, Thursday, 18'th Dec 2025
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) CEO Neil Kumar sold 30,011 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, December 15th. The shares were sold at an
Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO
04:12am, Friday, 12'th Dec 2025
Frontier Capital Management Co. LLC lowered its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 30.4% during the undefined quarter, according to the company in its most recent disclosure with the
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle's disappointing earnings after the bell yesterday. The Federal Reserve's 25-basis-p
Federated Hermes Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO
04:56am, Thursday, 11'th Dec 2025
Federated Hermes Inc. bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exc
Edgestream Partners L.P. Makes New $1.92 Million Investment in BridgeBio Pharma, Inc. $BBIO
04:10am, Saturday, 06'th Dec 2025
Edgestream Partners L.P. purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the undefined quarter, according to the company in its most recent disclosure with the Securities a
American Century Companies Inc. Buys 62,646 Shares of BridgeBio Pharma, Inc. $BBIO
04:26am, Saturday, 29'th Nov 2025
American Century Companies Inc. raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 6.1% in the undefined quarter, according to its most recent disclosure with the SEC. The firm own
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of “Moderate Buy” by Analysts
02:12am, Thursday, 27'th Nov 2025
Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-one ratings firms that are currently covering the firm, Marketbeat r
BridgeBio to Participate in December Investor Conferences
07:30am, Tuesday, 25'th Nov 2025
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
Biotech Stock Could Turn 4-Year Peak Into Records
03:29pm, Monday, 24'th Nov 2025
BridgeBio Pharma Inc (NASDAQ:BBIO) stock is up 3.3% to trade at $70.36 at last check, and earlier hit a fresh four-year high $70.60 on a bounce off its 20-day moving average.
BridgeBio Pharma: Set For New Commercial Launches After Trial Successes
07:04am, Sunday, 23'rd Nov 2025
BridgeBio has surged 90% since April 2025, driven by major clinical trial successes and robust commercial execution. BBIO's BBP-418 and Encaleret trials both exceeded expectations, each targeting bill
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Wednesday, 19'th Nov 2025
PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases,
